• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Comprehensive analysis of glutathione-related molecular changes induced by inhibition of GGCT

Research Project

Project/Area Number 21K09342
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 56030:Urology-related
Research InstitutionShiga University of Medical Science

Principal Investigator

Kageyama Susumu  滋賀医科大学, 医学部, 教授 (50378452)

Co-Investigator(Kenkyū-buntansha) 富田 圭司  滋賀医科大学, 医学部, 非常勤講師 (30640148)
茶野 徳宏  滋賀医科大学, 医学部, 准教授 (40346028)
吉田 哲也  滋賀医科大学, 医学部, 助教 (60510310)
窪田 成寿  滋賀医科大学, 医学部, 助教 (80759118)
河内 明宏  滋賀医科大学, 医学部, 客員教授 (90240952)
草場 拓人  滋賀医科大学, 医学部, 助教 (90847211)
Project Period (FY) 2021-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2023: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2022: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2021: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywordsγ-グルタミルシクロトランスフェラーゼ / グルタチオン / 抗癌療法 / がん / γーグルタミルシクロトランスフェラーゼ / 抗がん治療
Outline of Research at the Start

GGCTは申請者らが同定した癌増殖促進因子で、新規の癌治療標的として有用であり、GGCT阻害による正常組織への悪影響は極めて限定的である。しかしながら、GGCTはグルタチオン代謝に関わる重要な酵素の一つでもあるため、臨床応用に向かうためには、GGCT阻害時の周辺代謝の変化を解析することが必須である。申請者らは安全なGGCT標的抗癌治療を確立するために、GGCT阻害細胞の網羅的代謝解析を実施する。

Outline of Final Research Achievements

(1) The expression patterns of the γ-glutamyl cycle component enzyme groups (GGT, GCLM, GCLC, GSS, and OPLAH) were examined by GGCT knockdown, and no significant changes were found. (2) A comparison of the expression of enzymes constituting the γ-glutamyl cycle and sensitivity to the GGCT inhibitor showed no specific correlation. (3) Knockdown of CHAC1, CHAC2, and GGACT, which are known as the GGCT family genes, showed similar inhibition of cancer cell proliferation as GGCT. However, these three genes showed growth inhibition in normal cells, suggesting that GGCT is still the best target molecule for cancer therapy. (4) In renal cancer cell lines, a decrease in intracellular glutathione was observed upon Pro-GA treatment. Furthermore, the rescue effect of NAC or exogenous glutathione was confirmed, suggesting that the mechanism of cell injury by GGCT inhibition is a decrease in intracellular glutathione followed by an increase in reactive oxygen species (ROS), leading to cell death.

Academic Significance and Societal Importance of the Research Achievements

グルタチオン関連酵素からは、GGCT抗癌治療の予後予測バイオマーカーを同定することが出来なかったが、本研究により、GGCT抗癌作用の一端を明らかにすることが出来た。

Report

(4 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • Research Products

    (20 results)

All 2023 2022 2021

All Journal Article (15 results) (of which Int'l Joint Research: 3 results,  Peer Reviewed: 15 results,  Open Access: 6 results) Presentation (5 results)

  • [Journal Article] Identification of c-Met as a novel target of γ-glutamylcyclotransferase2023

    • Author(s)
      Saito Y, Taniguchi K, Ii H, Horinaka M, Kageyama S, Nakata S, Ukimura O, Sakai T
    • Journal Title

      Sci Rep

      Volume: 13 Issue: 1 Pages: 11922-11922

    • DOI

      10.1038/s41598-023-39093-7

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Development of an activity-based chemiluminogenic probe for γ-glutamylcyclotransferase2023

    • Author(s)
      Nohara Y, Taniguchi K, Ii H, Masuda S, Kawakami H, Matsumoto M, Hattori Y, Kageyama S, Sakai T, Nakata S, Yoshiya T
    • Journal Title

      Org Biomol Chem

      Volume: 21 Issue: 29 Pages: 5977-5984

    • DOI

      10.1039/d3ob00655g

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population2023

    • Author(s)
      Fujiwara Ryo、yuasa Takeshi、kobayashi kenichi、yoshida tetsuya、kageyama susumu
    • Journal Title

      Expert Review of Anticancer Therapy

      Volume: 23 Issue: 5 Pages: 461-469

    • DOI

      10.1080/14737140.2023.2200170

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Spinal Transection Switches the Effect of Metabotropic Glutamate Receptor Subtype 7 from the Facilitation to Inhibition of Ejaculation2023

    • Author(s)
      Masugi-Tokita Miwako、Kubota Shigehisa、Kobayashi Kenichi、Yoshida Tetsuya、Kageyama Susumu、Sakamoto Hirotaka、Kawauchi Akihiro
    • Journal Title

      Neuroscience

      Volume: 509 Pages: 10-19

    • DOI

      10.1016/j.neuroscience.2022.11.012

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Developments in personalized therapy for metastatic renal cell carcinoma2022

    • Author(s)
      Fujiwara Ryo、Kageyama Susumu、Yuasa Takeshi
    • Journal Title

      Expert Review of Anticancer Therapy

      Volume: 22 Issue: 6 Pages: 647-655

    • DOI

      10.1080/14737140.2022.2075347

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Regeneration of Functional Bladder Using Cell-seeded Amnion and P(LA/CL) Scaffolds2022

    • Author(s)
      Horii Tsunehito、Jonin Kazuyoshi、Kageyama Susumu、Yoshida Tetsuya、Kobayashi Kenichi、Minato Hiroshi、Ueda Joe、Tsujimoto Hiroyuki、Hagiwara Akeo、Ichikawa Hiroshi、Kawauchi Akihiro
    • Journal Title

      Tissue Engineering Part A

      Volume: 28 Issue: 23-24 Pages: 968-976

    • DOI

      10.1089/ten.tea.2022.0078

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] The γ-Glutamylcyclotransferase Inhibitor Pro-GA Induces an Antiproliferative Effect Through the Generation of Mitochondrial Reactive Oxygen Species2022

    • Author(s)
      II HIROMI、TANIGUCHI KEIKO、YOSHIYA TAKU、NOHARA YUKIE、KAGEYAMA SUSUMU、KAWAUCHI AKIHIRO、NAKATA SUSUMU
    • Journal Title

      Anticancer Research

      Volume: 42 Issue: 9 Pages: 4311-4317

    • DOI

      10.21873/anticanres.15931

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Androgen receptor axis?targeted agents are not superior to conventional hormonal therapy for treatment of metastatic prostate cancer2022

    • Author(s)
      Wada Akinori、Narita Mitsuhiro、Nagasawa Masayuki、Kusaba Takuto、Kubota Shigehisa、Yoshida Tetsuya、Johnin Kazuyoshi、Kawauchi Akihiro、Kageyama Susumu
    • Journal Title

      Oncology Letters

      Volume: 24 Issue: 4 Pages: 333-333

    • DOI

      10.3892/ol.2022.13453

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Prognostic nutritional index of early post?pembrolizumab therapy predicts long?term survival in patients with advanced urothelial carcinoma2022

    • Author(s)
      Kageyama Susumu、Yoshida Tetsuya、Kobayashi Kenichi、Wada Akinori、Nagasawa Masayuki、Kubota Shigehisa、Kusaba Takuto、Jo Fumiyasu、Nakagawa Shota、Johnin Kazuyoshi、Narita Mitsuhiro、Kawauchi Akihiro
    • Journal Title

      Oncology Letters

      Volume: 25 Issue: 2 Pages: 49-49

    • DOI

      10.3892/ol.2022.13635

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Population?based prostate?specific antigen screening for prostate cancer may have an indirect effect on early detection through opportunistic testing in Kusatsu City, Shiga, Japan2022

    • Author(s)
      Kageyama Susumu、Okinaka Yuki、Nishizawa Koji、Yoshida Toru、Ishitoya Satoshi、Shichiri Yasumasa、Kim Chul、Iwata Tsuyoshi、Yokokawa Ryusei、Arai Yutaka、Nishikawa Zenkai、Soga Hiroki、Ushida Hiroshi、Sakano Yuji、Naya Yoshio、Wada Akinori、Nagasawa Masayuki、Yoshida Tetsuya、Narita Mitsuhiro、Kawauchi Akihiro
    • Journal Title

      Molecular and Clinical Oncology

      Volume: 18 Issue: 1 Pages: 3-3

    • DOI

      10.3892/mco.2022.2599

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Cryptotanshinone, a novel pyruvate dehydrogenase kinase 4 inhibitor, suppresses cell invasiveness in bladder cancer cells via the mTOR/β-catenin/N-cadherin axis.2021

    • Author(s)
      Chul Jang Kim, Tokio Terado, Yukihiro Tambe, Ken-ichi Mukaisho, Susumu Kageyama, Akihiro Kawauchi, Hirokazu Inoue
    • Journal Title

      International Journal of Oncology

      Volume: 59 Issue: 1 Pages: 40-51

    • DOI

      10.3892/ijo.2021.5220

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Single short retention instillation of pirarubicin prevents intravesical recurrence of low-risk non muscle invasive bladder cancer2021

    • Author(s)
      Susumu Kageyama, koki Maeda, Shigehisa Kubota, Tetsuya Yoshida, Takashi Osafune, Yutaka Arai, Hiroki Soga, Zenkai Nishikawa, Yuji Sano, Keita Takimoto, Chul Jang Kim, Tokuhiro Chano, Akihiro Kawauchi
    • Journal Title

      in vivo

      Volume: 35 Issue: 2 Pages: 1141-1145

    • DOI

      10.21873/invivo.12360

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] γ-Glutamylcyclotransferase, a novel regulator of HIF-1α expression, triggers aerobic glycolysis2021

    • Author(s)
      Taniguchi Keiko、Kageyama Susumu、Moyama Chiami、Ando Shota、Ii Hiromi、Ashihara Eishi、Horinaka Mano、Sakai Toshiyuki、Kubota Shigehisa、Kawauchi Akihiro、Nakata Susumu
    • Journal Title

      Cancer Gene Therapy

      Volume: - Issue: 1 Pages: 37-48

    • DOI

      10.1038/s41417-020-00287-0

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Journal Article] Fluorizoline blocks the interaction between prohibitin-2 and γ-glutamylcyclotransferase and induces p21Waf1/Cip1 expression in MCF7 breast cancer cells2021

    • Author(s)
      Takagi Hiroko、Moyama Chiami、Taniguchi Keiko、Ando Kota、Matsuda Ryohei、Ando Shota、Ii Hiromi、Kageyama Susumu、Kawauchi Akihiro、Chouha Nora、Dёsaubry Laurent、Nakata Susumu
    • Journal Title

      Molecular Pharmacology

      Volume: 101 Issue: 2 Pages: 78-86

    • DOI

      10.1124/molpharm.121.000334

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Effects of Fiber Diameter and Spacing Size of an Artificial Scaffold on the In Vivo Cellular Response and Tissue Remodeling2021

    • Author(s)
      T Horii, H Tsujimoto, A Hagiwara, N Isogai, Y Sueyoshi, Y Oe, S Kageyama, T Yoshida, K Kobayashi, H Minato, J Ueda, H Ichikawa, A Kawauchi
    • Journal Title

      ACS Applied Bio Materials

      Volume: 4(9) Issue: 9 Pages: 6924-6936

    • DOI

      10.1021/acsabm.1c00572

    • NAID

      120007159522

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Int'l Joint Research
  • [Presentation] c-Met発現低下を介したγ-glutamylcyclotrasnferase(GGCT)阻害による前立腺がん細胞増殖抑制の新規分子機構の解明(Identification of c-Met as a novel target of gamma-glutamylcyclotrasnferase in a prostate cancer cell line)2023

    • Author(s)
      齋藤 友充子, 谷口 恵香, 飯居 宏美, 堀中 真野, 影山 進, 中田 晋, 浮村 理, 酒井 敏行
    • Organizer
      第110回日本泌尿器科学会総会
    • Related Report
      2023 Annual Research Report
  • [Presentation] メタボローム解析を用いた泌尿器癌関連疲労バイオマーカーの探索2023

    • Author(s)
      沖中勇輝,片岡洋祐,草場拓人,窪田成寿,永澤誠之,和田晃典,小林憲市,吉田哲也,影山 進,河内明宏
    • Organizer
      第32回泌尿器科分子・細胞研究会
    • Related Report
      2022 Research-status Report
  • [Presentation] 転移性去勢抵抗性前立腺癌に対するRadium-223の治療成績2022

    • Author(s)
      永澤誠之、和田晃典、吉田哲也, 影山 進, 成田充弘, 河内明宏
    • Organizer
      日本泌尿器腫瘍学会第8回学術集会
    • Related Report
      2022 Research-status Report
  • [Presentation] γ-グルタミルトランスフェラーゼ阻害薬によるMCF7乳がん細胞の増殖抑制効果に対するミトコンドリアROS産生の寄与2022

    • Author(s)
      飯居 宏美, 野瀬 梢, 茂山 千愛美, 安藤 翔太, 谷口 恵香, 吉矢 拓, 野原 由江, 影山 進, 中田 晋
    • Organizer
      第95回日本生化学会大会
    • Related Report
      2022 Research-status Report
  • [Presentation] オミックス解析に基づくGGCT発現阻害による抗腫瘍メカニズムの解明と膀胱癌治療への応用2021

    • Author(s)
      窪田成寿、礒野高敬, 吉田哲也, 影山 進, 成田充弘, 河内明宏
    • Organizer
      第109回日本泌尿器科学会総会
    • Related Report
      2021 Research-status Report

URL: 

Published: 2021-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi